Abstract

The main objective of the present investigation was to develop sustained release tablets of Lornoxicam a highly potent nonsteroidal anti-inflammatory drug with short half-life, that are characterized by initial burst drug release in the stomach and comply with the release requirements of sustained-release products using polymer and hydrophilic wax viz. HPMC K-15 M, PEG 6000. Sustained release tablets were prepared by melt granulation technique in which PEG 6000 used as a binder. This technique is better than a conventional granulation due to no water or organic solvents is needed. The process is less time consuming and uses less energy than wet granulation. Melt granulation is a useful technique to enhance the solubility and dissolution rate of poorly water-soluble drug.  The tablets were evaluated for physical characteristics like hardness, weight variation, friability and drug content. All the physical characters of the fabricated tablet were within acceptable limits. In-vitro release of drug was performed in 0.1 N HCl and phosphate buffer pH 6.8 for 12 hr. employing USP Type –II (paddle) at 50 rpm. The FTIR study revealed that there was no chemical interaction between drug and excipients. The drug release profile of the best formulation was well controlled and uniform throughout the dissolution studies. The drug release of optimized formulation follows the Higuchi kinetic model.